FPT 155

Drug Profile

FPT 155

Alternative Names: FPT155

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Five Prime Therapeutics
  • Class Antibodies; Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action CD274 antigen inhibitors; CD28 antigen stimulants; Cytotoxic T-lymphocyte antigen 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 30 Oct 2017 Five Prime Therapeutics announces intention to submit IND application for FPT 155 for Cancer in mid-2018
  • 26 Oct 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the 29th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2017)
  • 04 May 2017 Preclinical trials in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top